Host APOBEC3G protein inhibits HCV replication through direct binding at NS3

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Zhu, Yan Ping ^a   Peng, Zong Gen ^a   Wu, Zhou Yi ^a   Li, Jian Rui ^a   Huang, Meng Hao ^a   Si, Shu Yi ^a   Jiang, Jian Dong ^a,b  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; HELICASE; NONSTRUCTURAL PROTEIN 3; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE; NS3 PROTEIN, HEPATITIS C VIRUS; PROTEIN BINDING; VIRAL PROTEIN;

AFFINITY CHROMATOGRAPHY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DEAMINATION; ENZYME ACTIVITY; HEPATITIS C; HEPATITIS C VIRUS; MOLECULAR DOCKING; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SEQUENCE HOMOLOGY; VIRUS REPLICATION; CELL LINE; HEPACIVIRUS; HOST PATHOGEN INTERACTION; HUMAN; INTRACELLULAR SPACE; METABOLISM; MOLECULAR MODEL; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

HEPATITIS C VIRUS;

APOBEC-3G DEAMINASE; CELL LINE; CYTIDINE DEAMINASE; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; INTRACELLULAR SPACE; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN INTERACTION MAPS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84926300883     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121608     Document Type: Article

References (31)

1. Takaori-Kondo A. APOBEC family proteins: novel antiviral innate immunity. Int J Hematol. 2006; 83: 213-216. PMID: 16720550
2. Izumi T, Shirakawa K, Takaori-Kondo A. Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy. Mini Rev Med Chem. 2008; 8: 231-238. PMID: 18336343
3. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002; 418: 646-650. PMID: 12167863
4. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003; 424: 94-98. PMID: 12808465
5. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003; 424: 99-103. PMID: 12808466
6. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 2003; 302: 1056-1060. PMID: 14564014
7. Peng ZG, Zhao ZY, Li YP, Wang YP, Hao LH, Fan B, et al. Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus. Hepatology. 2011; 53:1080-1089. doi: 10.1002/hep.24160 PMID: 21480314
8. Nathans R, Cao H, Sharova N, Ali A, Sharkey M, Stranska R, et al. Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol. 2008; 26: 1187-1192. doi: 10.1038/nbt.1496 PMID: 18806783
9. Cen S, Peng ZG, Li XY, Li ZR, Ma J, Wang YM, et al. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J Biol Chem. 2010; 285: 16546-16552. doi: 10.1074/jbc.M109.085308 PMID: 20363737
10. Nguyen DH, Gummuluru S, Hu J. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol. 2007; 81: 4465-4472. PMID: 17314171
11. Narvaiza I, Linfesty DC, Greener BN, Hakata Y, Pintel DJ, Logue E, et al. Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog. 2009; 5: e1000439. doi: 10.1371/journal.ppat.1000439 PMID: 19461882
12. Fehrholz M, Kendl S, Prifert C, Weissbrich B, Lemon K, Rennick L, et al. The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses. J Gen Virol. 2012; 93: 565-576. doi: 10.1099/vir.0.038919-0 PMID: 22170635
13. Peng ZG, Fan B, Du NN, Wang YP, Gao LM, Li YH, et al. Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA. Hepatology. 2010; 52: 845-853. doi: 10.1002/hep.23766 PMID: 20593456
14. Xu P, Duong DM, Peng J. Systematical optimization of reverse-phase chromatography for shotgun proteomics. J Proteome Res. 2009; 8: 3944-3950. doi: 10.1021/pr900251d PMID: 19566079
15. Sudo K, Inoue H, Shimizu Y, Yamaji K, Konno K, Shigeta S, et al. Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography. Antiviral Res. 1996; 32: 9-18. PMID: 8863991
16. Sudo K, Yamaji K, Kawamura K, Nishijima T, Kojima N, Aibe K, et al. High-throughput screening of low molecular weight NS3-NS4A protease inhibitors using a fluorescence resonance energy transfer substrate. Antivir Chem Chemother. 2005; 16: 385-392. PMID: 16329285
17. Krawczyk M, Stankiewicz-Drogon A, Haenni AL, Boguszewska-Chachulska A. Fluorometric assay of hepatitis C virus NS3 helicase activity. Methods Mol Biol. 2010; 587: 211-221. doi: 10.1007/978-1-60327-355-8-15 PMID: 20225152
18. Wardell AD, Errington W, Ciaramella G, Merson J, McGarvey MJ. Characterization and mutational analysis of the helicase and NTPase activities of hepatitis C virus full-length NS3 protein. J Gen Virol. 1999; 80 (Pt 3): 701-709.
19. Holden LG, Prochnow C, Chang YP, Bransteitter R, Chelico L, Sen U, et al. Crystal structure of the antiviral APOBEC3G catalytic domain and functional implications. Nature. 2008; 456: 121-124. doi: 10.1038/nature07357 PMID: 18849968
20. Friew YN, Boyko V, Hu WS, Pathak VK. Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology. 2009; 6: 56. doi: 10.1186/1742-4690-6-56 PMID: 19497112
21. Komohara Y, Yano H, Shichijo S, Shimotohno K, Itoh K, Yamada A. High expression of APOBEC3G in patients infected with hepatitis C virus. J Mol Histol. 2006; 37: 327-332. PMID: 17036163
22. Vartanian JP, Henry M, Marchio A, Suspene R, Aynaud MM, Guétard D, et al. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog. 2010; 6: e1000928. doi: 10.1371/journal.ppat.1000928 PMID: 20523896
23. Kawaoka T, Aikata H, Takaki S, Hiramatsu A, Waki K, Hiraga N, et al. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat. 2011; 18: e550-560. doi: 10.1111/j.1365-2893.2011.01468.x PMID: 21914076
24. Casey LC, Lee WM. Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol. 2013; 29: 243-249. doi: 10.1097/MOG.0b013e32835ff972 PMID: 23563981
25. Welsch C, Zeuzem S. Clinical relevance of HCV antiviral drug resistance. Curr Opin Virol. 2012; 2: 651-655. doi: 10.1016/j.coviro.2012.08.008 PMID: 23006585
26. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol. 2013; 58: 583-592. doi: 10.1016/j.jhep.2012.10.019 PMID: 23104162
27. Ploss A, Dubuisson J. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut. 2012; 61 Suppl 1: i25-35. doi: 10.1136/gutjnl-2012-302048 PMID: 22504917
28. Wang YP, Liu F, He HW, Han YX, Peng ZG, Li BW, et al. Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus. Antimicrob Agents Chemother. 2010; 54: 2070-2077. doi: 10.1128/AAC.01764-09 PMID: 20176893
29. Zeisel MB, Lupberger J, Fofana I, Baumert TF. Host-targeting agents for prevention and treatment of chronic hepatitis C-perspectives and challenges. J Hepatol. 2013; 58: 375-384. doi: 10.1016/j.jhep.2012.09.022 PMID: 23041307
30. Ejima T, Hirota M, Mizukami T, Otsuka M, Fujita M. An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G. Int J Mol Med. 2011; 28: 613-616. doi: 10.3892/ijmm.2011.737 PMID: 21725586
31. Mohammed I, Parai MK, Jiang X, Sharova N, Singh G, Stevenson M, et al. SAR and Lead Optimization of an HIV-1 Vif-APOBEC3G Axis Inhibitor. ACS Med Chem Lett. 2012; 3: 465-469. PMID: 24533175